European Investment Bank

Cellectis S.A. is a clinical-stage biotechnological company headquartered in Paris, France, focused on developing immuno-oncology products utilizing gene-edited T-cells that express chimeric antigen receptors to target cancer cells. The company's primary portfolio includes several allogeneic T-cell product candidates such as UCART19, designed for treating CD19-expressing hematologic malignancies, and UCART123 for acute myeloid leukemia. Additional candidates include ALLO-501 for relapsed/refractory diffuse large B-cell lymphoma, UCART22 for B-cell acute lymphoblastic leukemia, and products targeting multiple myeloma, such as UCARTCS1 and ALLO-715. In addition to its therapeutic developments, Cellectis also produces high oleic soybean oil and other agricultural products. The company has established strategic partnerships with various institutions, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to innovate in the field of gene editing and immunotherapy.

Cellectis S.A. is a clinical-stage biotechnological company headquartered in Paris, France, focused on developing immuno-oncology products utilizing gene-edited T-cells that express chimeric antigen receptors to target cancer cells. The company's primary portfolio includes several allogeneic T-cell product candidates such as UCART19, designed for treating CD19-expressing hematologic malignancies, and UCART123 for acute myeloid leukemia. Additional candidates include ALLO-501 for relapsed/refractory diffuse large B-cell lymphoma, UCART22 for B-cell acute lymphoblastic leukemia, and products targeting multiple myeloma, such as UCARTCS1 and ALLO-715. In addition to its therapeutic developments, Cellectis also produces high oleic soybean oil and other agricultural products. The company has established strategic partnerships with various institutions, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to innovate in the field of gene editing and immunotherapy.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Prophesee SA, founded in 2014 and based in Paris, France, specializes in advanced machine vision sensors and systems through its innovative neuromorphic vision technology. Originally known as Chronocam SAS, the company rebranded in 2018 to reflect its pioneering approach to computer vision, which mimics the human eye and brain by detecting essential motion information rather than capturing a series of images. This unique Metavision® method enables Prophesee to achieve exceptional performance metrics, including high-speed time resolution, dynamic range, and significant reductions in data volume and power consumption. Its technology caters to a diverse range of industries, including biomedical, gaming, industrial automation, mobile devices, robotics, security, and automotive applications. Prophesee's team of over 100 engineers holds more than 50 international patents and has established a global presence with offices in cities such as Grenoble, Shanghai, Tokyo, and Silicon Valley, supported by a network of prominent investors.

Kayrros is a leading advanced data analytics company that specializes in providing actionable insights for the global energy market. With a team of over 100 employees from more than 15 nationalities, Kayrros operates from its headquarters in Paris and has additional offices in Houston, London, New York, and Singapore. The company integrates alternative and market data to create unique product offerings that enhance decision-making across the energy sector. Its platform focuses on environmental intelligence and asset observation, delivering critical insights related to greenhouse gas reduction, ecosystem protection, and energy transition management. Kayrros aims to support governments, companies, and investment markets in assessing the climate impact of energy and industrial activities, thereby enabling faster and more informed decisions. The company’s solutions are designed to be scalable and continuously expand to include new geographic regions and data sources, enhancing transparency in energy markets worldwide.

Prophesee SA, founded in 2014 and based in Paris, France, specializes in advanced machine vision sensors and systems through its innovative neuromorphic vision technology. Originally known as Chronocam SAS, the company rebranded in 2018 to reflect its pioneering approach to computer vision, which mimics the human eye and brain by detecting essential motion information rather than capturing a series of images. This unique Metavision® method enables Prophesee to achieve exceptional performance metrics, including high-speed time resolution, dynamic range, and significant reductions in data volume and power consumption. Its technology caters to a diverse range of industries, including biomedical, gaming, industrial automation, mobile devices, robotics, security, and automotive applications. Prophesee's team of over 100 engineers holds more than 50 international patents and has established a global presence with offices in cities such as Grenoble, Shanghai, Tokyo, and Silicon Valley, supported by a network of prominent investors.

NAVYA is a leading French name in the autonomous vehicle market and in smart shared mobility solutions. With more than 200 employees in France (Paris and Lyon) and in the United States (Michigan), NAVYA develops, manufactures and commercializes autonomous, driverless, and electric vehicles that combine robotic, digital and driving technologies at the highest level. Since 2015, NAVYA has been the first to market and put into service autonomous mobility solutions, shuttles and cabs. NAVYA has a range of two autonomous vehicles: the AUTONOM®SHUTTLE, launched in September 2015, of which more than 100 have already been produced as of today and 89 sold in 17 countries as of June 30, 2018, notably in the United States, France, Germany, Switzerland, Japan and Australia, and the AUTONOM®CAB, unveiled in November 2017 and whose first road tests will start shortly.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Electro Power Systems (EPS) operates in the sustainable energy sector, focusing on hybrid-storage solutions and microgrids that convert intermittent renewable energy into reliable power sources. Headquartered in Paris, with research, development, and manufacturing facilities in Italy, EPS has developed innovative energy storage technologies protected by 125 patents and applications, built on over a decade of research and development. The company aims to stabilize electrical grids with high levels of renewable energy integration in developed nations and to provide affordable off-grid power solutions in emerging economies without relying on subsidies. EPS has successfully executed 36 large-scale projects, including off-grid hybrid systems powered by renewable energy and energy storage, totaling over 35 MW of installed power. These systems serve more than 165,000 customers daily and include an additional 18 MW of grid support systems, resulting in a total capacity output of 47 MWh across 21 countries, spanning Europe, Latin America, Asia, and Africa.